Cardiff Oncology shares plunge after Q2 earnings miss
In a challenging market environment, Adverum Biotechnologies Inc. (NASDAQ:ADVM) stock has reached a 52-week low, dipping to $4.01. The biotechnology firm, which specializes in gene therapy targeting unmet medical needs in serious ocular and rare diseases, has faced significant headwinds over the past year, reflected in a stark 1-year change with a decline of -70.28%. According to InvestingPro data, the company maintains a strong liquidity position with a current ratio of 5.82, though five analysts have recently revised their earnings expectations downward. Investors have shown concern as the company navigates through the complexities of clinical developments and regulatory hurdles, leading to a cautious stance on the stock’s near-term prospects. The current price level marks the lowest the stock has traded in the past year, setting a critical benchmark for the company’s market valuation. InvestingPro analysis suggests the stock is currently undervalued, with additional insights available in the comprehensive Pro Research Report, which provides deep-dive analysis of this and 1,400+ other US stocks.
In other recent news, Adverum Biotechnologies has been the subject of several analyst adjustments. Mizuho (NYSE:MFG) Securities reduced the price target for Adverum from $20.00 to $16.00, yet maintained an Outperform rating. This followed Adverum’s announcement of robust study data for its leading gene therapy candidate, ixo-vec, which resulted in Mizuho increasing its peak sales estimate by approximately 45% to $2.6 billion.
In contrast, RBC Capital Markets adjusted its price target for Adverum to $10.00 from $12.00. H.C. Wainwright maintained its Buy rating and $30.00 price target, while Oppenheimer kept its Outperform rating with a $28.00 price target. Truist Securities revised its target from $60.00 to $40.00.
Adverum recently reported promising results from its LUNA Phase 2 trial and the long-term OPTIC study for Ixo-vec. The company also appointed Jason L. Mitchell as its new Chief Commercial Officer, anticipated to enhance Ixo-vec’s launch and commercialization. Adverum’s second quarter financial results for 2024 were strong, with earnings per share of ($0.89) surpassing both firm and consensus estimates. These are recent developments for Adverum Biotechnologies.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.